Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

LAG3 Inhibition Decreases AML-Induced Immunosuppression and Improves T Cell-Mediated Killing

Haitham Abdelhakim, MD, Luis M. Cortez, BS, Meizhang Li, PhD, Mitchell Braun, BS, Barry S. Skikne, MD, Tara L. Lin, MD, Neil Dunavin, MD, Andrew K Godwin, PhD

Blood (2019) 134 (Supplement_1): 3605.

https://doi.org/10.1182/blood-2019-129455

Published: 2019

Journal Articles

Conditioning Regimen Intensity May Affect Outcome in MDS Patients Undergoing Allogeneic Stem Cell Transplantation, Depending on MDS Subgroup

Barry S. Skikne, MD, Anurag K. Singh, MD, Sunil Abhyankar, MD, Tara L. Lin, MD, Leyla Shune, MD, Neil Dunavin, MD, Ajoy L. Dias, MD, Brian McClune, DO, Abdulraheem Yacoub, MD, Clint Divine, Haitham Abdelhakim, MD, Siddhartha Ganguly, MD, Jennifer Hanses, Carol E Webb, BA, Joseph P. McGuirk, DO

Blood (2019) 134 (Supplement_1): 5743.

https://doi.org/10.1182/blood-2019-130828

Published: 2019

Journal Articles

Health Care Reimbursement and Service Utilization Among Medicare Beneficiaries with Multiple Myeloma Receiving Autologous Hematopoietic Cell Transplantation in Inpatient and Outpatient Settings

Neil Dunavin, MD, Lih-Wen Mau, PhD MPH, Christa Lea Meyer, MS, Clint Divine, Al-Ola Abdallah, MD, Susan Leppke, MPH, Anita D'Souza, MBBS, Ellen Denzen, MS, Wael Saber, MD MS, Linda J. Burns, MD, Siddhartha Ganguly, MD

Blood (2018) 132 (Supplement 1): 832.

https://doi.org/10.1182/blood-2018-99-118423

Published: 2018

Journal Articles

CRISPR/Cas9-Mediated Disruption of PD-L1 Reduces the T Cell Suppressive Effect of Wharton's Jelly Mesenchymal Stromal Cells and Their Extracellular Vesicles

Neil Dunavin, MD, Meizhang Li, PhD, Safinur Atay, PhD, Jim Mitchell, Rupal Soder, PhD, Sunil Abhyankar, MD, Joseph P. McGuirk, DO, Andrew K Godwin, PhD, Buddhadeb Dawn, MD

Blood (2018) 132 (Supplement 1): 5095.

https://doi.org/10.1182/blood-2018-99-116921

Published: 2018

Journal Articles

LAG3 Promotes Acute Myeloid Leukemia-Induced Immune Suppression

Haitham Abdelhakim, MD, Neil Dunavin, MD, Meizhang Li, PhD, Mitchell Braun, BS, Ahmed Elkhanany, MD, Tara L Lin, MD, Andrew K Godwin, PhD

Blood (2018) 132 (Supplement 1): 2414.

https://doi.org/10.1182/blood-2018-99-117784

Published: 2018

Journal Articles

Daratumumab, Pomalidomide, and Dexamethasone (DPd) As Salvage Treatment for Relapsed/Refractory Myeloma Eligible for High-Dose Chemotherapy/Autologous Stem Cell Transplantation

Al-Ola Abdallah, MD, Neil Dunavin, MD, Brian McClune, DO, Leyla Shune, MD, Ajoy L. Dias, MD, Zahra Mahmoudjafari, PhD, Erica Hochard, PhD, Joseph P. McGuirk, DO, Siddhartha Ganguly, MD

Blood (2018) 132 (Supplement 1): 5760.

https://doi.org/10.1182/blood-2018-99-117654

Published: 2018

Journal Articles

Daratumumab, Pomalidomide, and Dexamethasone (DPd) for the Treatment of Relapsed/Refractory Multiple Myeloma: A Single Institution Experience

Al-Ola Abdallah, MD, Neil Dunavin, MD, Brian McClune, DO, Leyla Shune, MD, Ajoy L. Dias, MD, Zahra Mahmoudjafari, PhD, Erica Hochard, PhD, Joseph P. McGuirk, DO, Siddhartha Ganguly, MD

Blood (2018) 132 (Supplement 1): 5642.

https://doi.org/10.1182/blood-2018-99-117497

Published: 2018

Journal Articles

Outcomes of Vdpace with Immunomodulator Treatment in Initial and Relapsed/Refractory Multiple Myeloma in a Single Center

Al-Ola Abdallah, MD, Joseph P. McGuirk, DO, Leyla Shune, MD, Erica Hochard, PhD, Neil Dunavin, MD, Zahra Mahmoudjafari, PhD, Siddhartha Ganguly, MD

Blood (2017) 130 (Supplement 1): 5422.

https://doi.org/10.1182/blood.V130.Suppl_1.5422.5422

Published: 2017

Journal Articles

Successful Management of Treatment-Emergent Chronic Graft-Versus-Host Disease of the Liver Following Nivolumab for Relapsed Hodgkin's Lymphoma after Allogeneic Stem Cell Transplant

Mitchell Braun, BS, Neil Dunavin, MD, Maxwell Pike, MD, Ajoy L. Dias, MD, Tara L. Lin, MD, Leyla Shune, MD, Siddhartha Ganguly, MD, Joseph P. McGuirk, DO, Anurag K. Singh, MD, Sunil Abhyankar, MD

Blood (2017) 130 (Supplement 1): 5492.

https://doi.org/10.1182/blood.V130.Suppl_1.5492.5492

Published: 2017

Journal Articles

Chemotherapy-Refractory Acute Myeloid Leukemia and Outcomes after Allogeneic Stem Cell Transplantation—a Single Center Analysis

Kapil Kohli, MD, Ajoy L. Dias, MD, Neil Dunavin, MD, Leyla Shune, MD, Tara L. Lin, MD, Sunil Abhyankar, MD, Anurag K. Singh, MD, Siddhartha Ganguly, MD, Joseph P. McGuirk, DO, Barry S. Skikne, MD

Blood (2017) 130 (Supplement 1): 5541.

https://doi.org/10.1182/blood.V130.Suppl_1.5541.5541

Published: 2017

Journal Articles

Incidence and Risk Factors of Epstein-Barr Virus Viremia in Patients Undergoing Haploidential Transplantation with Post Translant Cyclophosphamide

Ghulam Rehman Mohyuddin, MD, Shaun DeJarnette, Leyla Shune, MD, Tara L. Lin, MD, Neil Dunavin, MD, Ajoy L. Dias, MD, Siddhartha Ganguly, MD, Sunil Abhyankar, MD, Joseph P. McGuirk, DO, Anurag K. Singh, MD

Blood (2017) 130 (Supplement 1): 5557.

https://doi.org/10.1182/blood.V130.Suppl_1.5557.5557

Published: 2017

Journal Articles

Daratumumab Combined with Pomalidomide and Dexamethasone (DPd) for Patients with Relapsed/Refractory Multiple Myeloma in a Single Institution

Al-Ola Abdallah, MD, Joseph P. McGuirk, DO, Leyla Shune, MD, Neil Dunavin, MD, Zahra Mahmoudjafari, PhD, Erica Hochard, PhD, Siddhartha Ganguly, MD

Blood (2017) 130 (Supplement 1): 1856.

https://doi.org/10.1182/blood.V130.Suppl_1.1856.1856

Published: 2017

Journal Articles

Clofarabine Followed By Lenalidomide for Treatment of High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia- Preliminary Clinical Outcomes and Potential Immune-Modulating Effects

Prachi Jain, MD, Sawa Ito, MD PhD, Neil Dunavin, MD, Jeffrey K. Klotz, MD, Kit Lu, MD, Eleftheria Koklanaris, RN, BSN, Debbie Draper, RN, BSN, Jeanine Superata, RN, Fariba Chinian, Quan Yu, MS, Keyvan Keyvanfar, BS, Susan Wong, Pawel Muranski, MD, John Barrett, MD, Minoo Battiwalla, MDMS

Blood (2016) 128 (22): 5553.

https://doi.org/10.1182/blood.V128.22.5553.5553

Published: 2016

Journal Articles

Activity of the Telomerase Inhibitor GRN163L (Imetelstat) on Acute Myeloblastic Leukemia Blasts Is Enhanced By DNA Methyltransferase Inhibitors Irrespective of TERT Promoter Methylation Status

Caroline R Cantilena, BA, Xin Zhao, MD PhD, Sachiko Kajigaya, PhD, Neil Dunavin, MD, Xin Tian, PhD, Stephen A. Strickland, MD, Bipin N. Savani, MD, Sanjay R. Mohan, MD, Katayoun Rezvani, MDPhD, Xingmin Feng, PhD, Danielle M. Townsley, MD, Minoo Battiwalla, MDMS, Sawa Ito, MD, Austin John Barrett, MDFRCP,FRCPath

Blood (2015) 126 (23): 1267.

https://doi.org/10.1182/blood.V126.23.1267.1267

Published: 2015

Journal Articles

CD34+ Selection Avoids Methotrexate and Reduces the Severity of Oral Mucositis in TBI-Based Allogeneic Stem Cell Transplantation

Ankit Anand, MD, Prathima Anandi, MD, Jain A. Natasha, MD, Kit Lu, MD, Neil Dunavin, MD, Christopher S. Hourigan, MDPhD, Robert Q. Le, MDPhD, Puja D. Chokshi, MD, Sawa Ito, MD, David F. Stroncek, MD, Marianna Sabatino, MD, John Barrett, MD, Minoo Battiwalla, MDMS

Blood (2014) 124 (21): 3898.

https://doi.org/10.1182/blood.V124.21.3898.3898

Published: 2014

Journal Articles

A Novel Standardized Quantitative Suppression Assay Reveals a Diversity of Human Immune-Regulatory Cell Potency

Samantha Miner, Nancy F. Hensel, Bahey Salem, Neil Dunavin, MD, Kazushi Tanimoto, MD, Minoo Battiwalla, MD MS, Kit Lu, MD, Keyvan Keyvanfar, BS, Marianna Sabatino, David Stroncek, Patrick J Hanley, PhD, Catherine M. Bollard, MBChB, MD, Katayoun Rezvani, MD, PhD, Marcin Kortylewski, PhD, Pawel Muranski, MD, John Barrett, MD, Sawa Ito, MD

Blood (2014) 124 (21): 316.

https://doi.org/10.1182/blood.V124.21.316.316

Published: 2014

Journal Articles

Clinical Comorbidity Measures and Predictive Scores in Ex Vivo T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

Robert Q. Le, MD PhD, Xin Tian, Natasha A Jain, MD, Kit Lu, MD, Sawa Ito, MD, Debbie A Draper, RN, Prathima Anandi, MD, Christopher S. Hourigan, MDPhD, Neil Dunavin, MD, John Barrett, MD, Minoo Battiwalla, MDMS

Blood (2014) 124 (21): 2550.

https://doi.org/10.1182/blood.V124.21.2550.2550

Published: 2014

Journal Articles

Early Versus Delayed Autologous Stem Cell Transplant In Patients Receiving Novel Therapies for Multiple Myeloma

Neil Dunavin, MD, Joyce Habib, MD, Gary Phillips, MAS, Patrick Elder, MS, Meaghan Tranovich, Don M Benson, Jr., MD, Craig C. Hofmeister, MD, John C. Byrd, MD, Steven M. Devine, MD, Yvonne Efebera, MD

Blood (2010) 116 (21): 3564.

https://doi.org/10.1182/blood.V116.21.3564.3564

Published: 2010

Journal Articles

Analysis of 179 Patients with Newly Diagnosed Multiple Myeloma (MM) Treated with Novel Agents Followed by Autologous Stem Cell Transplantation (ASCT): a Retrospective Study

Joyce Habib, MD, Neil Dunavin, MD, Gary Phillips, MAS, Patrick Elder, MS, Meaghan Tranovich, Don M Benson, Jr., MD, Craig C. Hofmeister, MD, John C. Byrd, MD, Steven M. Devine, MD, Yvonne Efebera, MD

Blood (2010) 116 (21): 1343.

https://doi.org/10.1182/blood.V116.21.1343.1343

Published: 2010

NARROW

LAG3 Inhibition Decreases AML-Induced Immunosuppression and Improves T Cell-Mediated Killing

Conditioning Regimen Intensity May Affect Outcome in MDS Patients Undergoing Allogeneic Stem Cell Transplantation, Depending on MDS Subgroup

Health Care Reimbursement and Service Utilization Among Medicare Beneficiaries with Multiple Myeloma Receiving Autologous Hematopoietic Cell Transplantation in Inpatient and Outpatient Settings

CRISPR/Cas9-Mediated Disruption of PD-L1 Reduces the T Cell Suppressive Effect of Wharton's Jelly Mesenchymal Stromal Cells and Their Extracellular Vesicles

LAG3 Promotes Acute Myeloid Leukemia-Induced Immune Suppression

Daratumumab, Pomalidomide, and Dexamethasone (DPd) As Salvage Treatment for Relapsed/Refractory Myeloma Eligible for High-Dose Chemotherapy/Autologous Stem Cell Transplantation

Daratumumab, Pomalidomide, and Dexamethasone (DPd) for the Treatment of Relapsed/Refractory Multiple Myeloma: A Single Institution Experience

Outcomes of Vdpace with Immunomodulator Treatment in Initial and Relapsed/Refractory Multiple Myeloma in a Single Center

Successful Management of Treatment-Emergent Chronic Graft-Versus-Host Disease of the Liver Following Nivolumab for Relapsed Hodgkin's Lymphoma after Allogeneic Stem Cell Transplant

Chemotherapy-Refractory Acute Myeloid Leukemia and Outcomes after Allogeneic Stem Cell Transplantation—a Single Center Analysis

Incidence and Risk Factors of Epstein-Barr Virus Viremia in Patients Undergoing Haploidential Transplantation with Post Translant Cyclophosphamide

Daratumumab Combined with Pomalidomide and Dexamethasone (DPd) for Patients with Relapsed/Refractory Multiple Myeloma in a Single Institution

Clofarabine Followed By Lenalidomide for Treatment of High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia- Preliminary Clinical Outcomes and Potential Immune-Modulating Effects

Activity of the Telomerase Inhibitor GRN163L (Imetelstat) on Acute Myeloblastic Leukemia Blasts Is Enhanced By DNA Methyltransferase Inhibitors Irrespective of TERT Promoter Methylation Status

CD34+ Selection Avoids Methotrexate and Reduces the Severity of Oral Mucositis in TBI-Based Allogeneic Stem Cell Transplantation

A Novel Standardized Quantitative Suppression Assay Reveals a Diversity of Human Immune-Regulatory Cell Potency

Clinical Comorbidity Measures and Predictive Scores in Ex Vivo T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

Early Versus Delayed Autologous Stem Cell Transplant In Patients Receiving Novel Therapies for Multiple Myeloma

Analysis of 179 Patients with Newly Diagnosed Multiple Myeloma (MM) Treated with Novel Agents Followed by Autologous Stem Cell Transplantation (ASCT): a Retrospective Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only